{"id":76796,"date":"2026-01-27T12:07:27","date_gmt":"2026-01-27T12:07:27","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/"},"modified":"2026-01-27T12:07:27","modified_gmt":"2026-01-27T12:07:27","slug":"transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/","title":{"rendered":"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA"},"content":{"rendered":"<div>\n<p>SUNRISE, Fla., Jan.  27, 2026  (GLOBE NEWSWIRE) &#8212; Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy\u00ae Ellipta\u00ae<sup>1<\/sup> 100\/62.5\/25, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Based on the FDA\u2019s public records,<sup>2<\/sup> Transpire Bio believes that it was the first company to file an ANDA with a Paragraph IV certification under the provisions of the Hatch-Waxman Act. Should Transpire Bio be the first to file an ANDA against the RLD, the company may become eligible for 180 days of market exclusivity. In the U.S., Trelegy\u00ae Ellipta\u00ae is indicated for the maintenance treatment of asthma in patients 18 years and older and the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). According to the GSK Annual Report, Trelegy\u00ae Ellipta\u00ae recorded U.S. annual net sales of nearly $2.7 Billion<sup>3 <\/sup>in 2024.<\/p>\n<p>\u201cThe FDA\u2019s acceptance for filing of our ANDA for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy\u00ae Ellipta\u00ae, is another major milestone in advancing our complex generic franchise,\u201d said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. \u201cOur highly experienced team in South Florida continues to work tirelessly to achieve important milestones like this. We are now one step closer to providing patients suffering from asthma or COPD with an affordable option and improved access to this critical medication.\u201d \u201cThis milestone is a result of Transpire Bio\u2019s deep scientific and technical competence, and demonstrates Transpire Bio\u2019s strong capabilities in developing complex drug device combination products,\u201d said Dr. Abhishek Gupta, Chief Scientific Officer of Transpire Bio.<\/p>\n<p>In addition to its focused generic franchise, Transpire Bio is building a pipeline of innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF), with three assets in development. Transpire Bio is also developing therapies for Pulmonary Arterial Hypertension (PAH), Diabetes, Obesity, and neurological diseases. These products are being developed and manufactured in Transpire Bio\u2019s state-of-the-art manufacturing facilities located in South Florida, U.S.<\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"text-align:justify;\">Trelegy\u00ae Ellipta\u00ae is a registered trademark of the GSK group of companies<\/li>\n<li style=\"text-align:justify;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y5J2N5U-NB3s1otKG7QbbwmBKV-VKJQOehwGfVTGtf2d1zwYoXwnzSIBqecePKz7RWCdAqNORlPAGD2uwKrcmfDAg9W5lzYjVBS-kd9qbchWjYduX0kugPLXWzZmPm_DSRsXGGjd0koSXHuP3qHJSP4hUSC7DZAE1ivbfcLKOYZ9HQFs80gjdIAQ6TFcPrD5wzaCRLiFsY1vHRotJI7wiVGWOiVk-alZTuVuUC44-xAFNbu21NGrqsLzKhFbsLcNVtQVDT6RSL_iP9IcqVvy7IpooYSO9vMKCe-B87xSt7c=\" rel=\"nofollow\" target=\"_blank\" title=\"FDA\u2019s list of drug products for which an ANDA has been received by the Office of Generic Drugs containing a \u201cParagraph IV\u201d patent certification\">FDA\u2019s list of drug products for which an ANDA has been received by the Office of Generic Drugs containing a \u201cParagraph IV\u201d patent certification<\/a><\/li>\n<li style=\"text-align:justify;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d9qJn-ao4sHuX_pn6oDVPCkaEvBosujhCviX0czySnf_drXCmh8UjjDgZpfVS9rIMkI-3zNsFdAUT2Wt7OQQ2R9cQbFNjWYVlvMJYV7bTqOCGsXCILMkOCtYCpkHN06MlcMA6HlSt8Xo9m5YNpvhUXCVgQqFdRSHAH9s6-oz4pU=\" rel=\"nofollow\" target=\"_blank\" title=\"GSK Annual Report 2024\">GSK Annual Report 2024<\/a><\/li>\n<\/ol>\n<p align=\"justify\"><strong>About Transpire Bio Inc.<\/strong><br \/>Transpire Bio Inc. is an integrated US-based, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. Transpire Bio harnesses its inhaled drug delivery expertise to improve patients\u2019 lives by expanding access to important therapies and developing treatments for serious diseases where therapeutic options are significantly lacking. Transpire Bio has developed multiple proprietary inhalation technology platforms, including dry-powder inhalers and soft-mist inhalers. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mxeby13oimavxUIuTns50UzaVTh_WF1fJP_He9Hq5xeRi1wAgdQy1WgUr-6_j09SanM-RnSFc7GkGk-hBGz5qHUn6Jn0qHyqv_ascElTivE=\" rel=\"nofollow\" target=\"_blank\" title=\"www.transpirebio.com\">www.transpirebio.com<\/a>.<\/p>\n<p><strong>Corporate Inquiries<\/strong><br \/>info@transpirebio.com<br \/>+1 954.908.2233<\/p>\n<p><strong>Investor Inquiries<\/strong><br \/>Stuart Loesch<br \/>Chief Commercial Officer, Transpire Bio<br \/>Stuart.Loesch@transpirebio.com<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjU3NWNjMWQtMjczNS00NmYyLWE4ZmItZjU5NDFmOWVjMDViLTEzMDgwNDMtMjAyNi0wMS0yNy1lbg==\/tiny\/Transpire-Bio.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) &#8212; Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy\u00ae Ellipta\u00ae1 100\/62.5\/25, has been accepted for filing by [&#8230;]\n","protected":false},"author":1,"featured_media":76797,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-76796","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA\" \/>\n<meta property=\"og:description\" content=\"SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) &#8212; Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inha\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T12:07:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/01\/Transpire-Bio.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA\",\"datePublished\":\"2026-01-27T12:07:27+00:00\",\"dateModified\":\"2026-01-27T12:07:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/\"},\"wordCount\":493,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/\",\"name\":\"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-01-27T12:07:27+00:00\",\"dateModified\":\"2026-01-27T12:07:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/","og_locale":"en_US","og_type":"article","og_title":"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA","og_description":"SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) &#8212; Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inha","og_url":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-01-27T12:07:27+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/01\/Transpire-Bio.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA","datePublished":"2026-01-27T12:07:27+00:00","dateModified":"2026-01-27T12:07:27+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/"},"wordCount":493,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/","url":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/","name":"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-01-27T12:07:27+00:00","dateModified":"2026-01-27T12:07:27+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/transpire-bios-anda-for-generic-trelegy-ellipta-accepted-for-filing-by-the-u-s-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Transpire Bio\u2019s ANDA for Generic Trelegy\u00ae Ellipta\u00ae Accepted for Filing by the U.S. FDA"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/76796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=76796"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/76796\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/76797"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=76796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=76796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=76796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}